Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.

Who May Be Eligible (Plain English)

Inclusion Criteria - Age \>= 18 - Documented germline pathogenic or likely pathogenic BRCA1, BRCA2, ATM, or PALB2 mutation - If no history of PDAC in a first or second degree relative, age \>= 50 - If there is a history of PDAC in a first or second degree relative, minimum age of eligibility is 10 years younger than the age of onset of the youngest relative with pancreatic cancer Exclusion Criteria • Pregnancy Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria * Age \>= 18 * Documented germline pathogenic or likely pathogenic BRCA1, BRCA2, ATM, or PALB2 mutation * If no history of PDAC in a first or second degree relative, age \>= 50 * If there is a history of PDAC in a first or second degree relative, minimum age of eligibility is 10 years younger than the age of onset of the youngest relative with pancreatic cancer Exclusion Criteria • Pregnancy

Treatments Being Tested

OTHER

Collection of data from endoscopic ultrasound or MRI/MRCP of the abdomen

Participants in this study should be undergoing pancreatic cancer screening with endoscopic ultrasound or MRI as part of their standard care. These should typically be done at least every 12 months, and the imaging tests will be ordered as routine clinical tests and will be billed to the participant's insurance. This study does not cover the costs of these screening tests, however the study will track the results of these screening tests.

OTHER

Blood sample collection for research

Up to 40mL of blood may be collected for analysis at each screening examination.

Locations (1)

Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States